Loading...

Regeneron Pharmaceuticals

SWX:REGN
Snowflake Description

Flawless balance sheet with solid track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
REGN
SWX
$33B
Market Cap
  1. Home
  2. CH
  3. Pharmaceuticals & Biotech
Company description

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The last earnings update was 71 days ago. More info.


Add to Portfolio Compare Print
  • Regeneron Pharmaceuticals has significant price volatility in the past 3 months.
REGN Share Price and Events
7 Day Returns
0%
SWX:REGN
-0.2%
CH Biotechs
-0.9%
CH Market
1 Year Returns
-16.2%
SWX:REGN
-21.4%
CH Biotechs
4.8%
CH Market
REGN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Regeneron Pharmaceuticals (REGN) 0% 0% -11.1% -16.2% -19.3% -
CH Biotechs -0.2% 9% 9.4% -21.4% 21.2% 66.9%
CH Market -0.9% 0% 2% 4.8% 15.2% 12.8%
1 Year Return vs Industry and Market
  • REGN outperformed the Biotechs industry which returned -21.4% over the past year.
  • REGN underperformed the Market in Switzerland which returned 4.8% over the past year.
Price Volatility
REGN
Industry
5yr Volatility vs Market
Related Companies

REGN Value

 Is Regeneron Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Regeneron Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Regeneron Pharmaceuticals.

SWX:REGN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 21 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.6%
Perpetual Growth Rate 10-Year CH Government Bond Rate 3.3%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for SWX:REGN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CH Govt Bond Rate 3.3%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.33
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.325 (1 + (1- 21%) (2.18%))
1.233
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.23
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.28% + (1.233 * 5.96%)
10.62%

Discounted Cash Flow Calculation for SWX:REGN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Regeneron Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

SWX:REGN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 10.62%)
2020 2,326.60 Analyst x5 2,103.15
2021 2,730.25 Analyst x4 2,231.00
2022 3,295.50 Analyst x2 2,434.27
2023 3,608.00 Analyst x2 2,409.14
2024 3,872.25 Est @ 7.32% 2,337.27
2025 4,108.82 Est @ 6.11% 2,241.88
2026 4,324.91 Est @ 5.26% 2,133.14
2027 4,526.61 Est @ 4.66% 2,018.21
2028 4,718.87 Est @ 4.25% 1,901.86
2029 4,905.52 Est @ 3.96% 1,787.21
Present value of next 10 years cash flows $21,597.14
SWX:REGN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $4,905.52 × (1 + 3.28%) ÷ (10.62% – 3.28%)
$68,933.13
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $68,933.13 ÷ (1 + 10.62%)10
$25,114.14
SWX:REGN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $21,597.14 + $25,114.14
$46,711.28
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $46,711.28 / 109.17
$427.89
SWX:REGN Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in SWX:REGN represents 1.01827x of NasdaqGS:REGN
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.01827x
Value per Share
(Listing Adjusted, CHF)
= Value per Share (USD) x Listing Adjustment Factor
= $ 427.89 x 1.01827
CHF435.71
Value per share (CHF) From above. CHF435.71
Current discount Discount to share price of CHF304.89
= -1 x (CHF304.89 - CHF435.71) / CHF435.71
30%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Regeneron Pharmaceuticals is available for.
Intrinsic value
30%
Share price is CHF304.89 vs Future cash flow value of CHF435.71
Current Discount Checks
For Regeneron Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Regeneron Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Regeneron Pharmaceuticals's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Regeneron Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Regeneron Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SWX:REGN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $22.43
NasdaqGS:REGN Share Price ** NasdaqGS (2019-06-14) in USD $299.42
Europe Biotechs Industry PE Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 26.02x
Switzerland Market PE Ratio Median Figure of 174 Publicly-Listed Companies 17.97x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Regeneron Pharmaceuticals.

SWX:REGN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:REGN Share Price ÷ EPS (both in USD)

= 299.42 ÷ 22.43

13.35x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Regeneron Pharmaceuticals is good value based on earnings compared to the Europe Biotechs industry average.
  • Regeneron Pharmaceuticals is good value based on earnings compared to the Switzerland market.
Price based on expected Growth
Does Regeneron Pharmaceuticals's expected growth come at a high price?
Raw Data
SWX:REGN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 13.35x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 21 Analysts
7.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.11x
Switzerland Market PEG Ratio Median Figure of 124 Publicly-Listed Companies 2.25x

*Line of best fit is calculated by linear regression .

SWX:REGN PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 13.35x ÷ 7.8%

1.72x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Regeneron Pharmaceuticals is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Regeneron Pharmaceuticals's assets?
Raw Data
SWX:REGN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $86.22
NasdaqGS:REGN Share Price * NasdaqGS (2019-06-14) in USD $299.42
Switzerland Biotechs Industry PB Ratio Median Figure of 7 Publicly-Listed Biotechs Companies 1.01x
Switzerland Market PB Ratio Median Figure of 215 Publicly-Listed Companies 1.65x
SWX:REGN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:REGN Share Price ÷ Book Value per Share (both in USD)

= 299.42 ÷ 86.22

3.47x

* Primary Listing of Regeneron Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Regeneron Pharmaceuticals is overvalued based on assets compared to the CH Biotechs industry average.
X
Value checks
We assess Regeneron Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Regeneron Pharmaceuticals has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

REGN Future Performance

 How is Regeneron Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 21 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
7.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Regeneron Pharmaceuticals expected to grow at an attractive rate?
  • Regeneron Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 3.3%.
Growth vs Market Checks
  • Regeneron Pharmaceuticals's earnings growth is positive but not above the Switzerland market average.
  • Regeneron Pharmaceuticals's revenue growth is expected to exceed the Switzerland market average.
Annual Growth Rates Comparison
Raw Data
SWX:REGN Future Growth Rates Data Sources
Data Point Source Value (per year)
SWX:REGN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 21 Analysts 7.8%
SWX:REGN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 21 Analysts 6%
Switzerland Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 8.7%
Switzerland Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 45.3%
Switzerland Market Earnings Growth Rate Market Cap Weighted Average 10.9%
Switzerland Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SWX:REGN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 21 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SWX:REGN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 9,302 3,414 2,810 13
2022-12-31 8,898 3,254 2,629 13
2021-12-31 8,393 3,047 2,442 17
2020-12-31 8,000 2,868 2,377 21
2019-12-31 7,343 2,648 1,951 21
SWX:REGN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 6,911 2,473 2,428
2018-12-31 6,711 2,195 2,444
2018-09-30 6,365 2,033 1,798
2018-06-30 6,203 1,995 1,591
2018-03-31 6,065 1,570 1,428
2017-12-31 5,872 1,307 1,199
2017-09-30 5,517 1,118 1,278
2017-06-30 5,236 1,354 1,155
2017-03-31 4,979 1,784 963
2016-12-31 4,860 1,486 896
2016-09-30 4,732 1,377 797
2016-06-30 4,649 1,619 743

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Regeneron Pharmaceuticals's earnings are expected to grow by 7.8% yearly, however this is not considered high growth (20% yearly).
  • Regeneron Pharmaceuticals's revenue is expected to grow by 6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SWX:REGN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 21 Analyst Estimates (S&P Global) See Below

All data from Regeneron Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:REGN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 22.88 36.92 14.77 7.00
2022-12-31 21.71 34.56 15.52 7.00
2021-12-31 20.79 31.11 16.79 9.00
2020-12-31 20.23 27.03 16.94 11.00
2019-12-31 16.59 20.43 10.93 12.00
SWX:REGN Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 22.43
2018-12-31 22.65
2018-09-30 16.71
2018-06-30 14.84
2018-03-31 13.37
2017-12-31 11.27
2017-09-30 12.07
2017-06-30 10.96
2017-03-31 9.17
2016-12-31 8.55
2016-09-30 7.64
2016-06-30 7.14

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Regeneron Pharmaceuticals is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Regeneron Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Switzerland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Switzerland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Regeneron Pharmaceuticals has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

REGN Past Performance

  How has Regeneron Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Regeneron Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Regeneron Pharmaceuticals has delivered over 20% year on year earnings growth in the past 5 years.
  • Regeneron Pharmaceuticals's 1-year earnings growth exceeds its 5-year average (70% vs 38.7%)
  • Regeneron Pharmaceuticals's earnings growth has exceeded the Europe Biotechs industry average in the past year (70% vs 14.7%).
Earnings and Revenue History
Regeneron Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Regeneron Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:REGN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 6,911.10 2,427.50 1,636.20
2018-12-31 6,710.80 2,444.40 1,556.20
2018-09-30 6,365.44 1,797.58 1,474.80
2018-06-30 6,202.62 1,591.24 1,412.33
2018-03-31 6,064.71 1,427.57 1,354.35
2017-12-31 5,872.20 1,198.50 1,320.40
2017-09-30 5,516.61 1,278.11 1,236.46
2017-06-30 5,236.06 1,154.59 1,199.74
2017-03-31 4,978.57 963.07 1,184.87
2016-12-31 4,860.40 895.50 1,177.70
2016-09-30 4,731.68 797.40 1,146.71
2016-06-30 4,648.98 743.00 1,086.66
2016-03-31 4,434.97 741.42 969.21
2015-12-31 4,103.73 636.06 838.53
2015-09-30 3,807.98 571.16 718.88
2015-06-30 3,396.35 444.13 652.89
2015-03-31 3,063.43 345.84 575.03
2014-12-31 2,819.56 338.13 519.27
2014-09-30 2,627.64 344.84 426.05
2014-06-30 2,498.88 402.77 379.65
2014-03-31 2,290.82 393.79 355.38
2013-12-31 2,104.75 413.74 346.39
2013-09-30 1,908.94 797.96 305.07
2013-06-30 1,739.60 848.13 254.35
2013-03-31 1,586.35 837.49 229.59
2012-12-31 1,378.48 750.27 210.76
2012-09-30 1,086.85 226.42 189.37

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Regeneron Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Regeneron Pharmaceuticals used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Regeneron Pharmaceuticals's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Regeneron Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Regeneron Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

REGN Health

 How is Regeneron Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Regeneron Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Regeneron Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Regeneron Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Regeneron Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 9.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Regeneron Pharmaceuticals Company Filings, last reported 3 months ago.

SWX:REGN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 9,444.70 0.00 3,232.40
2018-12-31 8,757.30 0.00 2,809.90
2018-09-30 7,868.30 0.00 2,192.15
2018-06-30 7,186.43 0.00 1,683.52
2018-03-31 6,567.64 0.00 1,624.95
2017-12-31 6,144.10 0.00 1,409.50
2017-09-30 6,051.59 0.00 1,378.94
2017-06-30 5,520.74 0.00 1,267.85
2017-03-31 4,866.02 0.00 1,307.08
2016-12-31 4,449.25 0.00 1,038.68
2016-09-30 4,491.25 3.59 1,408.39
2016-06-30 4,076.51 3.70 1,045.16
2016-03-31 3,765.08 13.51 849.18
2015-12-31 3,654.84 10.80 1,045.22
2015-09-30 3,296.87 30.72 895.64
2015-06-30 3,338.46 30.36 604.25
2015-03-31 2,971.43 144.08 742.16
2014-12-31 2,550.25 146.77 900.48
2014-09-30 2,551.79 287.95 1,042.20
2014-06-30 2,368.84 282.26 816.91
2014-03-31 2,211.25 326.67 648.13
2013-12-31 1,952.08 320.32 693.98
2013-09-30 1,690.17 314.16 445.32
2013-06-30 1,493.34 308.12 537.51
2013-03-31 1,406.35 302.27 307.71
2012-12-31 1,245.39 296.52 308.10
2012-09-30 806.02 290.96 262.55
  • Regeneron Pharmaceuticals's level of debt (7.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (24% vs 7.5% today).
  • Debt is well covered by operating cash flow (348.4%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 83x coverage).
X
Financial health checks
We assess Regeneron Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Regeneron Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

REGN Dividends

 What is Regeneron Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Regeneron Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought CHF2,000 of Regeneron Pharmaceuticals shares you are expected to receive CHF0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Regeneron Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Regeneron Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SWX:REGN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 21 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 0.8%
Switzerland Market Average Dividend Yield Market Cap Weighted Average of 167 Stocks 3%
Switzerland Minimum Threshold Dividend Yield 10th Percentile 1.3%
Switzerland Bottom 25% Dividend Yield 25th Percentile 2%
Switzerland Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SWX:REGN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 4.00
2020-12-31 0.00 4.00
2019-12-31 0.00 4.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Regeneron Pharmaceuticals has not reported any payouts.
  • Unable to verify if Regeneron Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Regeneron Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Regeneron Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Regeneron Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Switzerland.
X
Income/ dividend checks
We assess Regeneron Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Regeneron Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Regeneron Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

REGN Management

 What is the CEO of Regeneron Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Schleifer Leonard S.
COMPENSATION $26,520,555
AGE 66
TENURE AS CEO 31.5 years
CEO Bio

Dr. Schleifer Leonard S., M.D., Ph.D. founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988. Dr. Schleifer served as the Chairman of Regeneron Pharmaceuticals from 1990 to 1994. Dr. Schleifer, together with Regeneron's founding scientist, Dr. Yancopoulos, built and has managed the Company over the past 30 years. With 30 years of experience as Chief Executive Officer of the Company, Dr. Schleifer brings to the board an incomparable knowledge of the Company, significant leadership experience, and an in-depth understanding of the complex research, drug development, and business issues facing companies in the biopharmaceutical industry. In 1992, he was appointed Clinical Professor of Neurology at the Cornell University Medical School and from 1984 to 1988 he served as an Assistant Professor of the Cornell University Medical School in the Departments of Neurology and Neurobiology. Dr. Schleifer has been an Executive Director of Regeneron Pharmaceuticals, Inc. since 1988. He serves as a Director of Biotechnology Industry Organization. He is a licensed physician and is certified in Neurology by the American Board of Psychiatry and Neurology. Dr. Schleifer received his M.D. and Ph.D. in Pharmacology from the University of Virginia.

CEO Compensation
  • Schleifer's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Schleifer's remuneration is higher than average for companies of similar size in Switzerland.
Management Team Tenure

Average tenure and age of the Regeneron Pharmaceuticals management team in years:

4.5
Average Tenure
59
Average Age
  • The tenure for the Regeneron Pharmaceuticals management team is about average.
Management Team

Schleifer Leonard S.

TITLE
Co-Founder
COMPENSATION
$27M
AGE
66
TENURE
31.5 yrs

George Yancopoulos

TITLE
Founding Scientist
COMPENSATION
$25M
AGE
59
TENURE
2.6 yrs

Bob Landry

TITLE
Executive VP of Finance & CFO
COMPENSATION
$9M
AGE
55
TENURE
5.8 yrs

Daniel Van Plew

TITLE
Executive VP and GM of Industrial Operations & Product Supply
COMPENSATION
$9M
AGE
46
TENURE
11.3 yrs

Marion McCourt

TITLE
Senior VP & Head of Commercial
COMPENSATION
$10M
AGE
59
TENURE
1.4 yrs

Joe LaRosa

TITLE
Executive VP
COMPENSATION
$3M
AGE
60
TENURE
7.8 yrs

Beth Levine

TITLE
Senior VP
AGE
55
TENURE
0.5 yrs

Hala Mirza

TITLE
Senior Vice President of Corporate Communications & Citizenship
TENURE
0.5 yrs

Sally Paull

TITLE
Senior Vice President of Human Resources
TENURE
3.3 yrs

Neil Stahl

TITLE
Executive Vice President of Research & Development
COMPENSATION
$9M
AGE
62
TENURE
18.6 yrs
Board of Directors Tenure

Average tenure and age of the Regeneron Pharmaceuticals board of directors in years:

21.5
Average Tenure
68.5
Average Age
  • The average tenure for the Regeneron Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Pindaros Vagelos

TITLE
Chairman of the Board
COMPENSATION
$6M
AGE
89
TENURE
24.5 yrs

Schleifer Leonard S.

TITLE
Co-Founder
COMPENSATION
$27M
AGE
66
TENURE
31.5 yrs

George Yancopoulos

TITLE
Founding Scientist
COMPENSATION
$25M
AGE
59
TENURE
18.5 yrs

George Sing

TITLE
Director
COMPENSATION
$1M
AGE
70
TENURE
31.5 yrs

Art Ryan

TITLE
Director
COMPENSATION
$1M
AGE
76
TENURE
16.5 yrs

Michael Brown

TITLE
Director
COMPENSATION
$1M
AGE
78
TENURE
28.1 yrs

Chris Poon

TITLE
Director
COMPENSATION
$1M
AGE
67
TENURE
8.7 yrs

Joseph Goldstein

TITLE
Director
COMPENSATION
$1M
AGE
79
TENURE
28.1 yrs

Marc Tessier-Lavigne

TITLE
Director
COMPENSATION
$1M
AGE
59
TENURE
7.7 yrs

Bonnie Bassler

TITLE
Director
COMPENSATION
$1M
AGE
57
TENURE
2.8 yrs
Who owns this company?
Recent Insider Trading
  • Regeneron Pharmaceuticals individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CHF) Value (CHF)
16. May 19 Sell Joseph Goldstein Individual 15. May 19 15. May 19 -1,000 CHF308.67 CHF-308,665
13. Mar 19 Sell Sanofi Company 08. Mar 19 08. Mar 19 -131,115 CHF415.23 CHF-54,442,843
14. Dec 18 Sell Pindaros Vagelos Individual 12. Dec 18 12. Dec 18 -6 CHF379.48 CHF-2,277
10. Sep 18 Sell Sanofi Company 06. Sep 18 06. Sep 18 -104,552 CHF393.87 CHF-41,180,318
X
Management checks
We assess Regeneron Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Regeneron Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

REGN News

Simply Wall St News

REGN Company Info

Description

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi, Bayer, Teva, Mitsubishi Tanabe Pharma, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Details
Name: Regeneron Pharmaceuticals, Inc.
REGN
Exchange: SWX
Founded: 1988
$32,170,290,239
109,166,142
Website: http://www.regeneron.com
Address: Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road,
Tarrytown,
New York, 10591,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS REGN Common Stock Nasdaq Global Select US USD 02. Apr 1991
DB RGO Common Stock Deutsche Boerse AG DE EUR 02. Apr 1991
LSE 0R2M Common Stock London Stock Exchange GB USD 02. Apr 1991
SWX REGN Common Stock SIX Swiss Exchange CH CHF 02. Apr 1991
WBAG REGN Common Stock Wiener Boerse AG AT EUR 02. Apr 1991
BMV REGN * Common Stock Bolsa Mexicana de Valores MX MXN 02. Apr 1991
BOVESPA REGN34 BDR EACH 1 REP 0.2 COM USD0.001 Bolsa de Valores de Sao Paulo BR BRL 20. May 2019
Number of employees
Current staff
Staff numbers
7,448
Regeneron Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/17 21:52
End of day share price update: 2019/06/14 00:00
Last estimates confirmation: 2019/07/16
Last earnings filing: 2019/05/07
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.